meloxicam/Finding
One finding, on its own
A single claim from the graph, with the evidence strength computed from its study, the sentence it was drawn from, and the paper. This address does not change.
No detected effect on hospital length of stay
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull result“The duration of hospital stay was numerically shorter for subjects who received meloxicam IV versus placebo, but the difference was not statistically significant (P =.4935) (Supplemental Digital Content 3, Table S2).”
Quoted verbatim from Safety and Efficacy of Perioperative Intravenous Meloxicam for Moderate-to-Severe Pain Management in Total Knee Arthroplasty: A Randomized Clinical Trial.. - Study
- RCT
- Dose
- 30 mg IV bolus before incision, then every 24 hours
- Population
- Adults undergoing elective primary total knee arthroplasty; hospital stay after surgery
Safety and Efficacy of Perioperative Intravenous Meloxicam for Moderate-to-Severe Pain Management in Total Knee Arthroplasty: A Randomized Clinical Trial.2021PMID:33502533Industry fundedPermalink
Keep reading
- Everything the graph holds on meloxicam
- Every compound studied against Hospital length of stay
- How to read the evidence strength and the marks
To cite this finding: https://catalystproject.ai/e/01M45R0XXBDGXMKB3VAPA5ADY8